Method for enhancing immune responses in mammals

Abstract

The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as an antibody, capable of specifically binding to the targeted immune system inhibitor.

Description

[0001]This application is a continuation of U.S. patent application Ser. No. 12 / 219,100, filed Jul. 16, 2008, which is a continuation of U.S. patent application Ser. No. 10 / 071,829, filed Feb. 7, 2002, now abandoned, which is a divisional application of U.S. patent application Ser. No. 09 / 444,144, filed Nov. 20, 1999, now U.S. Pat. No. 6,379,708, entitled “METHOD FOR ENHANCING IMMUNE RESPONSES IN MAMMALS.” The entire disclosures of U.S. patent application Ser. Nos. 09 / 444,144, 10 / 071,829 and 12 / 219,100 are incorporated herein by reference.[0002]This invention relates generally to the field of immunotherapy and, more specifically, to methods for enhancing host immune responses.BACKGROUND OF THE INVENTION[0003]The immune system of mammals has evolved to protect the host against the growth and proliferation of potentially deleterious agents. These agents include infectious microorganisms such as bacteria, viruses, fungi, and parasites which exist in the environment and which, upon intr...

AI Technical Summary

Benefits of technology

[0021]In a particularly useful embodiment, the binding partner is immobilized previously on a solid support to create an “absorbent matrix” (FIG. 1). The exposure of biological fluids to such an absorbent matrix will permit binding by the immune system inhibitor, thus, effecting a decrease in its abundance in the biological fluids. The treated biological fluid can be returned to the patient. The total volume of biological fluid to be treated and the treatment rate are parameters individualized for each patient, guided by the induction of vigorous immune responses while minimizing toxicity. The solid support (i.e., inert medium) can be composed of any material useful for such purpose, including, for example, hollow fibers, cellulose-based fibers, synthetic fibers, flat or pleated membranes, silica-based particles, or macroporous beads.

Problems solved by technology

Second, certain immune system inhibitors antagonize the binding of immune system stimulators to their receptors.

Third, particular immune system inhibitors exert their effects by binding to receptors on host cells and signalling a decrease in their production of immune system stimulators.

Fourth, certain immune system inhibitors act directly on immune cells, inhibiting their proliferation and function, thereby, decreasing the vigor of the immune response.

997)). In cases where the production of any of the aforementioned immune system inhibitors, either individually or in combination, dampens or otherwise alters immune responsiveness before the elimination of the pathogenic agent, a chronic infection may

These therapies have enjoyed limited success (Sidhu and Bollon, supra; Maas, et al., supra) due to the fact: 1) that at the levels employed they proved extremely toxic; and, 2) that each increases the plasma levels of the immune system inhibitor, sTNFRI (Lantz, et al., Cytokine 2: 402-406 (1990); Miles, et al., Brit. J. Cancer 66: 1195-1199 (1992)).

Although Ultrapheresis provides advantages over traditional therapeutic approaches, there are certain drawbacks that limit its clinical usefulness.

An additional drawback to Ultrapheresis is the significant loss of circulatory volume during treatment, which must be offset by the infusion of replacement fluid.

The chronic shortage of donor plasma, combined with the risks of infection by human immunodeficiency virus, hepatitis A, B, and C or other etiologic agents, represents a severe impediment to the widespread implementation of Ultrapheresis.

Images